A Phase 2 trial to investigate low-dose psilocybin's efficacy in treating generalized anxiety disorder
Latest Information Update: 24 Mar 2023
At a glance
- Drugs Psilocybin (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Diamond Therapeutics
- 21 Mar 2023 According to Diamond Therapeutics media release, Phase 2 study will be conducted in Canada on a take-at-home basis and has received Health Canada approval.
- 07 Dec 2022 According to Diamond Therapeutics media release, this Phase II study will be conducted in Canada under Health Canada regulations
- 24 Aug 2021 New trial record